References
- Hadzhieva B, Dimitrov M, Petkova V. Pharmaceutical regulation of herbal medicinal products in the countries of the European Union, the USA, Canada and Japan. Acta Medica Bulgarica. 2023;50(3):71-74.
- CIOMS Working Group. Drug-Induced Liver Injury: Current status and future directions. [Internet]. Geneva: CIOMS; 2020. Available from: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–1264.
- Stavrakeva K, Popova M, Esad M, et al. Drug-induced liver toxicity. Acta Medica Bulgarica. 2025;51(4):77-85.
- Li J, Zhao W, Wang R, et al. Mapping the incidence of drug-induced liver injury: A systematic review and meta-analysis. Liver Int.2023;43(12):2826–2837.
- FDA Drug Safety Communication: Risks of liver injury with leflunomide. [Internet]. U.S. Food and Drug Administration (FDA). 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-risk-liver-injury-leflunomide
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Leflu-nomide. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548725/
- Devarbhavi H, Ghabril M, Barnhart H, et al. Lefluno-mide-induced liver injury: Differences in characteristics and outcomes in Indian and U.S. registries. Liver Int. 2022;42(6):1323–1329.
- Mielnik P, Sexton J, Fagerli KM, et al. Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD). Rheumatol Adv Pract. 2023;7(2):rkad053.
- Miladi S, Ben Yacoub S, Boussâa H, et al. Leflunomide in rheumatoid arthritis: Factors associated with therapeutic maintenance. Revmatologia. 2024;32(1):5–11.
- Nikolov RP. Adverse reactions associated with the use of non-steroidal anti-inflammatory drugs and non-opioid analgesics. Revmatologia. 2010;18(1):18-27.
- Meunier L, Larrey D. Recent advances in hepatotoxicity of nonsteroidal anti-inflammatory drugs. Ann Hepatol. 2018;17(2):187–191.
- Kim S, Lee S, Lee J, Yu K. Modeling of aceclofenac metabolism to major metabolites in healthy volunteers. Biopharm Drug Dispos. 2016;37(9):480–491.
- Drug Interaction Report: diclofenac, leflunomide. [Internet]. Drugs.com. Available from: https://www.drugs.com/interactions-check.php?drug_list=869-0%2C1440-0&professional=1
- Ahmed T, Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024;16(2):186–192.
- Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815.
- Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The updated version. Int J Mol Sci. 2016;17(1):14.
- LiverTox: Roussel Uclaf Causality Assessment Method (RU-CAM) in Drug Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012; Updated 2019 May 4. Available from:https://www.ncbi.nlm.nih.gov/books/NBK548272
- Chalasani N, Younossi Z, Lavine JE, et al. AASLD Practice Guidance: Drug-Induced Liver Injury. Hepatology. 2017;65(6):2036–2094.
- Bokan G. Leflunomide hepatotoxicity in rheumatoid arthritis: Case report and literature review.Slovenian J Gastroenterol. 2024;2:1–5.
- Salmi AR, Islahudin F, Shamsuddin AF, Shahril NS. A study on leflunomide-induced liver injury in rheumatoid arthritis patients. Res J Pharm Technol. 2013;6(5):556–561.
- Chalasani NP, Hayashi PH, Bonkovsky HL, et al. The diagnosis and management of idiosyncratic drug induced liver injury. Am J Gastroenterol. 2014;109(7):950–966.
- Bessone F, Hillotte GL, Tamagnone N, et al. Ursodeoxycholic acid for the management of drug-induced liver injury: Role of hepatoprotective and anti-cholestatic mechanisms. J Clin Transl Hepatol. 2025;13(2):162–168.
- Li M, Luo Q, Tao Y, et al. Pharmacotherapies for drug-induced liver injury: A current literature review. Front Pharmacol. 2022;12:806249.